NEWSROOM

Biotechnology

Lipella Pharmaceuticals Abstract on Oral Lichen Planus Treatment Accepted for Podium Presentation at 2025 AAOM/EAOM International Meeting Conference on “Global Transformation in Oral Medicine”

Lipella Pharmaceuticals Abstract on Oral Lichen Planus Treatment Accepted for Podium Presentation at 2025 AAOM/EAOM International Meeting Conference on “Global Transformation in Oral Medicine”

Apr 23, 2025

Joint meeting to be held in Las Vegas, May 14-17 Presentation will be delivered by Dr. Alessandro Villa of Miami Cancer Institute Topline study results demonstrate clinically meaningful improvements in OLP Visible lesion resolution during treatment; return toward baseline post-dosing supports localized activity Listen: PITTSBURGH, April 23, 2025 - PRISM MediaWire - Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) ("Lipella," "we," "our," or the "Company"), a clinical-stage biotechnology company...

Aemetis India Plant Visited by U.S. Consul General

Aemetis India Plant Visited by U.S. Consul General

Apr 23, 2025

Listen: CUPERTINO, Calif., April 23, 2025 - PRISM MediaWire - Aemetis, Inc. (NASDAQ: AMTX), a diversified global renewable natural gas and biofuels company, announced the Company’s subsidiary in India, Universal Biofuels, has been working with the U.S. government to support the success of American interests in India. Aemetis owns and operates an 80 million gallon per year biodiesel production facility in Kakinada, Andhra Pradesh. The U.S. Consul General, Jennifer Larson, recently toured the...

Lipella Pharmaceuticals Abstract on Oral Lichen Planus Treatment Accepted for Podium Presentation at 2025 AAOM/EAOM International Meeting Conference on “Global Transformation in Oral Medicine”

Lipella Reports Positive Phase 2a Results from Second LP-310 Cohort in Oral Lichen Planus; Final Data Expected Q2 2025

Apr 22, 2025

Second Cohort Results Highlight Efficacy Across All Key Measures and Reinforce Safety of Twice-Daily Oral Rinse Phase 2a Study Now Fully Enrolled Across All Three Dose Cohorts Advancing Toward Phase 2b IND Submission and Broader Regulatory Engagement Listen: PITTSBURGH, April 22, 2025 - PRISM MediaWire - Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (“Lipella,” “our,” “us,” or the “Company”), a clinical-stage biotechnology company addressing serious diseases with significant unmet needs, today...

Aemetis India Plant Visited by U.S. Consul General

Aemetis India Plant Receives $31 million of Biodiesel Orders from OMCs for Delivery in Next Three Months

Apr 21, 2025

Listen: CUPERTINO, Calif., April 21, 2025 - PRISM MediaWire - Aemetis, Inc. (NASDAQ: AMTX), a diversified global renewable natural gas and biofuels company, announced the Company’s subsidiary in India, Universal Biofuels, received multiple orders for an aggregate of $31 million for the delivery during May, June and July of more than 33,000 kiloliters of biodiesel to the three government-owned Oil Marketing Companies (OMCs). Additional OMC orders are expected throughout the year in order to...

Aclarion Announces Publication of Seminal Nociscan Cost-Effectiveness Analysis

Aclarion Announces Publication of Seminal Nociscan Cost-Effectiveness Analysis

Apr 21, 2025

Independent Cost-Effectiveness Analysis Concludes Nociscan is Effective and Less Costly Compared to Provocative Discography Conclusions Illustrate Nociscan Saves $1,712 per Patient and Improves Surgical Success by 10% Listen: BROOMFIELD, Colo., April 21, 2025 - PRISM MediaWire - Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians...

PRISM MarketView Spotlights Opus Genetics in New Q&A with CEO George Magrath

PRISM MarketView Spotlights Opus Genetics in New Q&A with CEO George Magrath

Apr 15, 2025

Feature Details Company Milestones and 2025 Catalysts Across Gene Therapy and Ophthalmic Programs NEW YORK, April 15, 2025 - PRISM MediaWire - PRISM MarketView today published a Q&A feature with Dr. George Magrath, Chief Executive Officer of Opus Genetics, Inc. (“Opus Genetics” or the “Company”) (Nasdaq: IRD), a clinical-stage gene therapy company developing treatments for inherited retinal diseases (IRDs) and broader ophthalmic conditions. Dr. George Magrath, Chief Executive Officer of...

BioStem Technologies Reports Record Preliminary Fourth-Quarter Net Revenue of $102.9 Million and Preliminary Full-Year 2024 Revenue of $301.8 Million

BioStem Technologies Reports Record Preliminary Fourth-Quarter Net Revenue of $102.9 Million and Preliminary Full-Year 2024 Revenue of $301.8 Million

Apr 14, 2025

Company reports record preliminary fourth quarter net revenue of $102.9 Million, contributing to a total of $301.8 Million in revenue for 2024 Achieves preliminary GAAP net income of $15.5 million, or $0.94 per share, marking the fourth consecutive quarter of profitability Preliminary Q4 2024 Adjusted EBITDA of $11.1 Million Financial Results Conference Call and Webcast to be held on April 14, 2025 at 4:30 pm ET POMPANO BEACH, FL, April 14, 2025 - PRISM MediaWire - BioStem Technologies, Inc....

Aemetis India Plant Visited by U.S. Consul General

Aemetis Biogas Monthly RNG Production Increased by 55% in March

Apr 8, 2025

Sales of LCFS credits and D3 RINs completed at the end of Q1 CUPERTINO, Calif., April 08, 2025 - PRISM MediaWire - Aemetis, Inc. (NASDAQ: AMTX), a renewable natural gas and renewable fuels company focused on low and negative carbon intensity renewable fuels, announced today that its production of renewable natural gas (RNG) increased 55% in March compared to February. RNG production from anaerobic dairy digesters increases during periods of warmer weather due to improved temperatures for...

BioStem Technologies Reports Record Preliminary Fourth-Quarter Net Revenue of $102.9 Million and Preliminary Full-Year 2024 Revenue of $301.8 Million

BioStem Technologies to Host Fourth Quarter and Full Year 2024 Financial Results Conference Call on April 14, 2025

Apr 8, 2025

Conference Call and Webcast to be held at 4:30 PM ET POMPANO BEACH, Fla., April 08, 2025 - PRISM MediaWire - BioStem Technologies Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacture, and commercialization of placental-derived biologics for advanced wound care, announces that it will release its fourth quarter and full year 2024 financial results on Monday, April 14, 2025, and host a conference call and webcast at 4:30 PM ET. The webcast will feature an overview...

Lipella Pharmaceuticals Abstract on Oral Lichen Planus Treatment Accepted for Podium Presentation at 2025 AAOM/EAOM International Meeting Conference on “Global Transformation in Oral Medicine”

Lipella Pharmaceuticals Completes Enrollment in Phase 2a Trial of LP-310 for Oral Lichen Planus

Apr 8, 2025

Topline Results Expected Q2 2025 Listen: PITTSBURGH, April 08, 2025 - PRISM MediaWire - Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (“Lipella” or the “Company”), a clinical-stage biotechnology company focused on developing innovative therapies for unmet medical needs, today announced the completion of enrollment in its Phase 2a multicenter, dose-ranging trial evaluating LP-310, a liposomal tacrolimus oral rinse for the treatment of oral lichen planus (OLP). The Phase 2a trial has now fully...

BioStem Technologies Reports Record Preliminary Fourth-Quarter Net Revenue of $102.9 Million and Preliminary Full-Year 2024 Revenue of $301.8 Million

BioStem Technologies Announces Extension to File 2024 Annual Report with OTC

Apr 1, 2025

POMPANO BEACH, Fla., April 1, 2025 - PRISM MediaWire - BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company specializing in the development, manufacturing, and commercialization of placental-derived products for advanced wound care, announces it has filed for an extension to submit its annual report for the year ended December 31, 2024 to the OTC The company is currently undergoing a mandatory Securities Exchange Commission (SEC) review process related to its Form 10 registration...

BioStem Technologies Reports Record Preliminary Fourth-Quarter Net Revenue of $102.9 Million and Preliminary Full-Year 2024 Revenue of $301.8 Million

BioStem Announces Notice of Allowance for Two U.S. Patent Applications

Mar 31, 2025

Company continues to innovate and strengthen its patent portfolio with 43 issued patents and 26 pending for its advanced wound care technology POMPANO BEACH, Fla., March 31, 2025 - PRISM MediaWire - BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of...

Digital Utilities Ventures Secures $3.4M Contract to Deploy Easy FEN™ Sustainable Agriculture Units in Africa

Digital Utilities Ventures Secures $3.4M Contract to Deploy Easy FEN™ Sustainable Agriculture Units in Africa

Mar 27, 2025

Pioneering Green Technology to Transform Food Security and Agricultural Productivity Key Highlights: Sustainable Agriculture Solution for AfricaDigital Utilities Ventures (DUTV) has secured a $3.4 million contract to deploy its patent pending Easy FEN™ modular units in Northern Africa. These advanced systems will convert 35,000 tons of biomass and food waste annually into 5.4 million gallons of Terreplenish®, an organic liquid microbial fertilizer. This initiative supports sustainable farming...

Digital Utilities Ventures Acquires Lifestyle Dock Company, and Expands Market Reach for Easy NanoVoid™ Technology

Digital Utilities Ventures Acquires Lifestyle Dock Company, and Expands Market Reach for Easy NanoVoid™ Technology

Mar 25, 2025

Acquisition Provides Strategic East Coast Manufacturing Facility and Strengthens International Distribution Capabilities Key Highlights: Strategic Acquisition for Market Expansion: Digital Utilities Ventures (OTC: DUTV) acquires Lifestyle Dock Company (LDC), unlocking a potential $3.4 million in additional revenue and expanding the reach of its patented Easy NanoVoid™ water purification technology. This acquisition enhances DUTV’s presence in the luxury dock and marina market, introducing...

Oncocyte Reports Successful 2024; Sets Stage for 2025 Catalysts

Oncocyte Reports Successful 2024; Sets Stage for 2025 Catalysts

Mar 24, 2025

Q4 2024 revenue of $1.5 million in pharma services; full year revenue of $1.9 million GraftAssure RUO assay launched July 2024 Signed strategic partner and investor, Bio-Rad Laboratories Fully funded clinical kitted product development with $50+ million in equity raises Advanced science in transplant; achieved Medicare claims expansion IRVINE, Calif., March 24, 2025 - PRISM MediaWire - Oncocyte Corp. (Nasdaq: OCX), a diagnostics technology company, today published the following letter to...

Oncocyte to Release Fourth Quarter 2024 Results on March 24, 2025

Oncocyte to Release Fourth Quarter 2024 Results on March 24, 2025

Mar 18, 2025

IRVINE, Calif., March 18, 2025 - PRISM MediaWire - Oncocyte Corp. (Nasdaq: OCX), a pioneering diagnostics technology company, today announced that it will report fourth quarter 2024 financial results after the market closes on Monday, March 24, 2025. Oncocyte will host a live Zoom webinar to discuss the company's financial results at 2:00 p.m. PT that same day. The live webinar to discuss financial results, followed by Q&A, will be accessible via registration: Register here An archived...

BioStem Technologies Reports Record Preliminary Fourth-Quarter Net Revenue of $102.9 Million and Preliminary Full-Year 2024 Revenue of $301.8 Million

BioStem Receives Institutional Review Board (IRB) Approval to Advance Clinical Trial Demonstrating the Therapeutic Benefits of BioREtain® Technology in Treating Venous Leg Ulcers

Feb 24, 2025

Study comparing BioStem’s proprietary amnion chorion allograft versus the standard of care aims to demonstrate superior outcomes, further validating its clinical efficacy to support market expansion POMPANO BEACH, FL, February 24, 2025 - PRISM MediaWire - BioStem Technologies, Inc. a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, announces Institutional Review Board (IRB) approval for a clinical...

Oncocyte to Release Fourth Quarter 2024 Results on March 24, 2025

Oncocyte to Participate in BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference

Feb 11, 2025

IRVINE, Calif., Feb. 11, 2025 - PRISM MediaWire - Oncocyte Corp. (Nasdaq: OCX), a pioneering diagnostics technology company, today announced that Chief Executive Officer Josh Riggs and Chief Financial Officer Andrea James will attend BTIG’s MedTech, Digital Health, Life Science & Diagnostic Tools Conference in Snowbird, Utah. Oncocyte will host one-on-one meetings with interested investors. Investors attending the conference wishing to schedule a meeting are encouraged to contact BTIG to...

Lipella Pharmaceuticals Reports Positive Topline Phase 2a Results for LP-310 in the Treatment of Oral Lichen Planus

Lipella Pharmaceuticals Reports Positive Topline Phase 2a Results for LP-310 in the Treatment of Oral Lichen Planus

Feb 11, 2025

LP-310 Treatment Demonstrates Clinically Meaningful Reductions in Pain, Ulceration, and Inflammation Across All Key Metrics Findings Highlight Favorable Safety Profile and Tolerability of Twice-Daily Oral Rinse Multicenter Phase 2a Trial Advancing to Higher Treatment Dose with Recruitment Expected to Conclude the First Half of 2025 Lipella Leadership to Present Findings at BIO CEO & Investor Conference on Tuesday, February 11, 2025, at 2:30 p.m. EST PITTSBURGH, Feb. 11, 2025 - PRISM...

Oncocyte to Release Fourth Quarter 2024 Results on March 24, 2025

Oncocyte Prices $29.1 Million Equity Offering

Feb 10, 2025

Proceeds Expected to Fund Transplant Assay Through FDA IVD Clearance and Commercial Launch Strategic Partner Bio-Rad Invests, Boosts Support for Trial and Commercialization IRVINE, Calif., Feb. 10, 2025 - PRISM MediaWire - Oncocyte Corp. (Nasdaq: OCX), a pioneering diagnostics technology company, today announced that it has entered into securities purchase agreements with existing investors for a registered direct offering (“Registered Direct Offering”) and concurrent private placement (“PIPE...

Aclarion Announces Publication of Seminal Nociscan Cost-Effectiveness Analysis

Aclarion Announces Northwestern Medicine as First CLARITY Trial Site

Feb 6, 2025

Northwestern Medicine is a global leader in clinical trial research, including spine CLARITY is a randomized study designed to demonstrate Nociscan’s ability to improve surgical outcomes while reducing costs for chronic low back pain Nociscan aims to become the gold standard in identifying sources of low back pain through MR Spectroscopy (MRS) and Augmented Intelligence (AI) BROOMFIELD, Colo., Feb. 6, 2025 - PRISM MediaWire - Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW),...

Lipella Pharmaceuticals Reports Positive Topline Phase 2a Results for LP-310 in the Treatment of Oral Lichen Planus

Lipella Pharmaceuticals Granted FDA Approval for Expanded Access Program for LP-310 in Oral Lichen Planus

Feb 6, 2025

PITTSBURGH, February 6, 2025 - PRISM MediaWire - Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (“Lipella” or the “Company”), a clinical-stage biotechnology company focused on developing innovative therapies for unmet medical needs, today announced that the U.S. Food and Drug Administration (FDA) has granted approval for an Expanded Access Program (EAP) for LP-310, an oral rinse formulation designed to treat oral lichen planus (OLP). LP-310 is an innovative, localized therapy formulated to...

Aclarion Announces Publication of Seminal Nociscan Cost-Effectiveness Analysis

Aclarion Announces CLARITY Trial for Nociscan Now Fully Funded

Feb 4, 2025

The Company has secured nearly $20 million in gross proceeds in 2025 ensuring complete funding for its pivotal CLARITY trial CLARITY is a prospective, randomized, multicenter study to validate Nociscan’s ability to improve surgical outcomes Nociscan aims to become the gold standard in identifying sources of low back pain through MR Spectroscopy (MRS) and Augmented Intelligence (AI) Broomfield, CO, February 4, 2025 - PRISM MediaWire - Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON,...

Aclarion to Showcase Groundbreaking NOCISCAN Technology at the Selby Spine Conference

Aclarion to Showcase Groundbreaking NOCISCAN Technology at the Selby Spine Conference

Jan 31, 2025

Dr. Sigurd Berven to Highlight NOCISCAN Capabilities, Combining MR Spectroscopy and Augmented Intelligence (AI) NOCISCAN as New Gold Standard in Identifying a Source of Discogenic Pain BROOMFIELD, Colo., January 31, 2025 - PRISM MediaWire - Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain,...

Argentum 47, Inc. Announces Acquisition of Marelius Biopharma Group, Divestiture of Argentum Data Solutions, and Leadership Transition

Argentum 47, Inc. Announces Acquisition of Marelius Biopharma Group, Divestiture of Argentum Data Solutions, and Leadership Transition

Jan 21, 2025

Las Vegas, NV, January 21, 2025 - PRISM MediaWire - Argentum 47, Inc. (OTC PINK: ARGQ) (“Argentum” or the “Company”) today announced a series of transformative developments, including the acquisition of Marelius Biopharma Group (MBG), the divestiture of Argentum Data Solutions, and a leadership transition aimed at strengthening the Company’s strategic focus and shareholder value. Acquisition of Marelius Biopharma Group Argentum has acquired Marelius Biopharma Group (MBG), a UK-based company...

Digital Utilities Ventures Secures $3.4M Contract to Deploy Easy FEN™ Sustainable Agriculture Units in Africa

Digital Utilities Ventures, Inc. Announces Strategic Partnership with TradersQue LLC to Support Growth and Expansion Initiatives

Jan 15, 2025

Mankato, MN, January 15th, 2025 - PRISM MediaWire - Digital Utilities Ventures (OTC: DUTV), a green solutions company focused on regenerative agriculture and clean water technologies, is pleased to announce a strategic partnership with TradersQue LLC (www.TradersQue.com). The collaboration aims to leverage TradersQue’s innovative business solutions to support DUTV’s ongoing growth and expansion efforts across the Agricultural and other new markets. This partnership will provide DUTV with...

BioStem Technologies Announces Record Preliminary Fourth Quarter Net Revenue of $102.9 Million, with Full-Year 2024 Net Revenue Expected to Reach $301.8 Million

BioStem Technologies Announces Record Preliminary Fourth Quarter Net Revenue of $102.9 Million, with Full-Year 2024 Net Revenue Expected to Reach $301.8 Million

Jan 13, 2025

POMPANO BEACH, Fla., January 13, 2025 - PRISM MediaWire - BioStem Technologies, Inc. (OTC: BSEM) (“BioStem”, “we”, “us”, or “our”), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, today announced selected preliminary financial results for the fiscal fourth quarter and full year ended December 31, 2024. 2024 Preliminary Fourth Quarter and Year End Results: Fourth quarter net revenue is expected to...

Klotho Neurosciences to Present at Biotech Showcase 2025 during J.P. Morgan Healthcare Week in San Francisco

Klotho Neurosciences to Present at Biotech Showcase 2025 during J.P. Morgan Healthcare Week in San Francisco

Jan 8, 2025

Company to present at 3:00 p.m. PT on Tuesday, January 14, at the Hilton San Francisco Union Square New York, NY, January 8, 2025 - PRISM MediaWire - Klotho Neurosciences, Inc. (NASDAQ: KLTO), a specialty biotechnology company focused on developing cell and gene therapies for amyotrophic lateral sclerosis (ALS), Alzheimer’s, and Parkinson’s disease, announces that it will present at Biotech Showcase 2025, an event expected to include over 3,200 healthcare professionals with more than 1,200...

Oncocyte to Release Fourth Quarter 2024 Results on March 24, 2025

Oncocyte Appoints Dr. Paul Billings as Consulting Chief Medical Officer

Jan 8, 2025

Dr. Billings is a renowned diagnostics specialist with a history of commercializing novel assays in precision medicine Will provide key regulatory and reimbursement support Will assist business development efforts and strategic partnerships Irvine, Calif., Jan. 8, 2025 - PRISM MediaWire - Oncocyte Corp. (NASDAQ: OCX), a diagnostics technology company, announces the appointment of Dr. Paul Billings as the company’s Consulting Chief Medical Officer. In this part-time role, he will support a...

BioStem Technologies Launches Clinical Trial to Demonstrate the Therapeutic Benefits of its BioREtain® Technology in Treating Diabetic Foot Ulcers Using Vendaje®

BioStem Technologies Launches Clinical Trial to Demonstrate the Therapeutic Benefits of its BioREtain® Technology in Treating Diabetic Foot Ulcers Using Vendaje®

Jan 8, 2025

Study of Vendaje® versus standard of care aims to show superior wound treatment, supporting market expansion POMPANO BEACH, Fla., January 8, 2025 - PRISM MediaWire - BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, announces the initiation of the BR-AM-DFU (BioREtain® Amniotic Membrane - Diabetic Foot Ulcers) clinical trial to evaluate Vendaje® versus...